Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

PSB-0739

Name: PSB-0739
Brand: TargetMol
SKU: T23195
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T23195Cas No. 1052087-90-7

Alias PSB0739

PSB-0739 Selective platelet P2Y12 receptor antagonist characterized by competitive binding and high affinity (Ki =24.9 nM) with antithrombotic and platelet aggregation modulating effects.

PSB-0739

Copy Product Info

😃Good

Catalog No. T23195Alias PSB0739Cas No. 1052087-90-7

PSB-0739 Selective platelet P2Y12 receptor antagonist characterized by competitive binding and high affinity (Ki =24.9 nM) with antithrombotic and platelet aggregation modulating effects.

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
1 mg	$69	7-10 days	7-10 days
5 mg	$299	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:Green

Resource Download

COA

Product Introduction

Bioactivity

Description	PSB-0739 Selective platelet P2Y12 receptor antagonist characterized by competitive binding and high affinity (Ki =24.9 nM) with antithrombotic and platelet aggregation modulating effects.
Targets&IC50	HIV-1 infection enhanced by SEVI:21.77  μM
In vitro	PSB-0739 inhibits the formation of semen-derived amyloid fibrils (SEVI), which enhance HIV-1 infection. It demonstrates direct anti-HIV activity with an IC₅₀ of 21.77 ± 5.15 μM, without significant cytotoxicity in HeLa cells at concentrations below 62.5 μM[1].
In vivo	In rat models, PSB-0739 administered intrathecally (0.01–0.3 mg/kg) significantly reduced CFA-induced inflammatory pain and sciatic nerve ligation-induced neuropathic pain, with a minimal effective dose of 0.1 mg/kg. It also increased pain thresholds in the hot plate test, indicating analgesic effects. Additionally, PSB-0739 decreased the expression of pro-inflammatory cytokines such as IL-1β and TNF-α in inflamed tissues (paw and spinal cord), suggesting its mechanism involves inhibition of cytokine signaling both centrally and peripherally[2].
Synonyms	PSB0739

Chemical Properties

Molecular Weight	609.54
Formula	C₂₆H₁₇N₃Na₂O₈S₂
Cas No.	1052087-90-7
Smiles	O=C1C2=C(C(C3=C(NC4=CC=C(C(S(=O)([O-])=O)=C4)NC5=CC=CC=C5)C=C(S(=O)([O-])=O)C(N)=C13)=O)C=CC=C2.[Na+].[Na+]
Relative Density.	no data available

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 1 mg/mL (1.64 mM), Sonication is recommended.

Solution Preparation Table

H2O

	1mg	5mg	10mg	50mg
1 mM	1.6406 mL	8.2029 mL	16.4058 mL	82.0291 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc